Antiepileptic drugs and suicidality

Area of Science:

• Neurology
• Psychiatry
• Pharmacology

Background:

• Patients with epilepsy exhibit a significantly elevated risk of suicide compared to the general population.
• The potential contribution of anti-epileptic drugs (AEDs) to suicidality has become a subject of recent scrutiny.
• The U.S. Food and Drug Administration (FDA) issued a class warning for AEDs in 2008 due to a meta-analysis.

Purpose of the Study:

• To review the association between epilepsy, AEDs, and psychiatric conditions, including suicidality.
• To discuss the significance and limitations of the FDA's 2008 findings on AEDs and suicidality.
• To evaluate options for suicidality screening in patients with epilepsy.

Main Methods:

• Review of existing literature and meta-analysis data concerning epilepsy, AEDs, and suicidality.
• Analysis of the FDA's 2008 meta-analysis findings and the subsequent class warning.
• Evaluation of current suicidality screening tools and their clinical applicability.

Main Results:

• A meta-analysis indicated a higher rate of suicidality in patients taking AEDs (0.43/1000) versus placebo (0.22/1000).
• The FDA's decision to issue a class warning for all AEDs, despite controversy, heightened awareness of psychiatric comorbidities.
• The findings have raised concerns about potential underutilization of beneficial AEDs due to perceived risks.

Conclusions:

• The relationship between epilepsy, AEDs, and suicidality is complex and warrants careful consideration.
• The FDA's warning, while controversial, has increased focus on psychiatric co-morbidity and suicidality screening in epilepsy patients.
• Implementing effective suicidality screening protocols is crucial for managing psychiatric risks in this population.